Suggestions
Eliad Josephson
Digital Health Executive | Pioneering Precision Health, Lab Data & Home Testing Innovation | Expert and Consultant in Business Development & Strategic Partnerships
Eliad Josephson is a Business Development Executive at Clarivate, based in Los Angeles, California.2 He has a diverse professional background that spans multiple industries and roles.
Professional Experience
Josephson's current position at Clarivate involves business development responsibilities.2 Prior to this role, he has held several notable positions:
- Co-Founder at Caligenix4
- Chief Operating Officer at BK Global Holdings4
- Executive Producer at RCR Media Group4
Education and Skills
Eliad Josephson attended Baruch College, which is part of the City University of New York system.1 His professional focus appears to be on innovation and challenging industry norms, as he states that his mission is to "innovate companies and products that challenge the industry status quo".1
Additional Information
Josephson describes himself as a "Real Estate Executive, Producer & Entrepreneur" on his about.me page.3 This aligns with his diverse professional background, which includes experience in healthcare, media production, and business operations.
While his LinkedIn profile username is indeed eliadjosephson1, it's worth noting that his professional experience extends beyond what is immediately visible on his LinkedIn profile, encompassing roles in various industries and entrepreneurial ventures.
Highlights
Revolutionizing clinical trials! This partnership between Walgreens and Biomedical Advanced Research and Development Authority (BARDA) marks a significant step forward in expanding the reach and accessibility of decentralized clinical trials. By leveraging Walgreens' extensive network of community pharmacies and healthcare services, this collaboration aims to enhance diversity in clinical research and ensure that critical drug development efforts are more inclusive and representative of the broader population. From a lab testing perspective, this collaboration could revolutionize how lab tests are integrated into clinical trials, making it easier to collect and analyze data from a more diverse pool of participants. The hybrid model of decentralized trials, combined with Walgreens' lab testing capabilities, offers a seamless way to bring clinical research closer to patients, ultimately improving trial efficiency and patient outcomes. The $100 million investment in this initiative underscores the importance of decentralized trials in advancing public health, particularly in preparing for and responding to emergencies. This innovative approach not only strengthens the healthcare infrastructure but also paves the way for more patient-centered research that integrates clinical trials into everyday healthcare experiences.
#DecentralizedClinicalTrials #HealthcareInnovation #LabTesting #ClinicalResearch #Pharma #PublicHealth #PatientCenteredCare #DiversityInResearch #DiagnosticTesting #StrategicPartnerships
Gene by Gene, a leading CLIA/CAP lab, is proud to announce a major investment in next-gen sequencing (#NGS) technology, reaffirming its commitment to further expanding advancements in its, already established, NGS capability. This strategic initiative aligns with Gene by Gene’s vision to enhance precision medicine and capitalize on the significant market opportunities projected by recent industry reports.
Building on over a decade of leadership in array testing, Gene by Gene is now positioning its lab to lead the next growth frontier in NGS. By leveraging its highly automated robotics labs, Gene by Gene ensures precision diagnostics, rapid turnaround times, and competitive pricing. This investment aligns with the company’s mission to empower its partners with comprehensive genetic data across all fields and make advanced genomic technology more accessible to a broader population.
"Investing in NGS is a critical step in our mission to lead the genetic testing industry and support the growing demand for advanced genomic solutions," said Dr. Lior Rauchberger, CEO of Gene by Gene. "With this enhanced capability, we are well-positioned to meet the needs of our clients and partners, drive innovation, and ensure that more people have access to the benefits of personalized medicine."
Recent industry reports indicate that the global NGS market is poised for exponential growth, driven by increasing applications in clinical diagnostics, personalized medicine, and research. Gene by Gene’s timely investment aims to leverage this growth, ensuring the company remains at the forefront of technological advancements and market trends while making these advancements more widely available.
"By adopting cutting-edge NGS technology, we are not only enhancing our lab capabilities but also expanding our reach into new and emerging markets," added Josh Wittner, President of Gene by Gene. "Our commitment to quality and innovation ensures that we provide our clients with the most accurate and actionable genetic data, ultimately improving patient outcomes and advancing scientific discovery."
Gene by Gene’s investment in NGS technology is accompanied by a comprehensive growth strategy, which includes partnerships with leading healthcare providers, research institutions, and biopharma companies. These collaborations are expected to drive further advancements in genomic research and clinical applications, reinforcing Gene by Gene’s position as a trusted leader in the genetic testing industry.
The democratization of cutting-edge technology not only enables more patients to benefit from personalized medicine but also acts as a catalyst for further research. By making these tools more accessible, Gene by Gene is fostering an environment where groundbreaking research can thrive, ultimately leading to new discoveries and treatments that can profoundly impact people’s lives and revolutionize medical care.
Please connect for #partnership & #businessdevelopment opportunities!
